FDA clears device for pediatric sleep apnea treatment

Vivos Therapeutics received FDA 510(k) clearance for its oral device to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children, according to a recent press release. This device, part of Vivos’ CARE line, offers a non-invasive, effective alternative to current treatments. Clearance was based on a multi-site study that enrolled patients ages 6 to 17 years of age.